Literature DB >> 7525471

Expression of CD44 variant transcripts in dog lymphatic tissue.

K F Milde1, R Alejandro, R L Pastori.   

Abstract

The gene of the CD44 cell surface glycoprotein consists of 20 exons. Ten exons known as variant exons are inserted by alternative RNA splicing between exon 5 and 16, thus generating diversity in the extracellular portion of the protein. We have cloned the dog cDNA homologue of the human variant exon region of CD44 and characterized its transcript expression in normal lymphatic tissues. Using PCR with primers complementary to regions contiguous to the insertion point and a variant exon, all ten variant exons of dog CD44 were detected in a high number of different isoforms. Transcripts containing the ten variable exons directly spliced to both sides of the insertion point were detected. We found an extensive usage of all variant exons from v1 to v10 in a high number of different combinations, some presenting a tissue-specific expression pattern. A similar complex profile of transcript expression was found in peripheral blood lymphocytes from rat and human.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525471     DOI: 10.1007/bf00177826

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  33 in total

1.  Structural heterogeneity of human Pgp-1 and its relationship with p85.

Authors:  M B Omary; I S Trowbridge; M Letarte; M F Kagnoff; C M Isacke
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

2.  Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells.

Authors:  W G Carter; E A Wayner
Journal:  J Biol Chem       Date:  1988-03-25       Impact factor: 5.157

3.  Genomic sequencing.

Authors:  G M Church; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

4.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.

Authors:  U Günthert; M Hofmann; W Rudy; S Reber; M Zöller; I Haussmann; S Matzku; A Wenzel; H Ponta; P Herrlich
Journal:  Cell       Date:  1991-04-05       Impact factor: 41.582

5.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

6.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

7.  Participation in normal immune responses of a metastasis-inducing splice variant of CD44.

Authors:  R Arch; K Wirth; M Hofmann; H Ponta; S Matzku; P Herrlich; M Zöller
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

8.  Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis.

Authors:  V B Lokeshwar; L Y Bourguignon
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

9.  CD44 expression on murine tissues.

Authors:  S J Kennel; T K Lankford; L J Foote; S G Shinpock; C Stringer
Journal:  J Cell Sci       Date:  1993-02       Impact factor: 5.285

10.  Variations in the cytoskeletal interaction and posttranslational modification of the CD44 homing receptor in macrophages.

Authors:  R L Camp; T A Kraus; E Puré
Journal:  J Cell Biol       Date:  1991-12       Impact factor: 10.539

View more
  2 in total

Review 1.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

2.  Functional analysis of CD44 variants and xCT in canine tumours.

Authors:  Atsushi Tanabe; Kento Kimura; Hana Tazawa; Takuya Maruo; Masayuki Taguchi; Hiroeki Sahara
Journal:  Vet Med Sci       Date:  2020-11-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.